Influences on the adoption of new pharmaceutical technologies: The example of the fentanyl patch

Clinical Research and Regulatory Affairs

Volumn 19, Issue 4, 2002, Pages 397-412

  Salmon, J Warren ^a   Lin, Swu Jane ^a   Crawford, Stephanie Y ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL;

ADVERTIZING; ARTICLE; DATA BASE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG USE; HEALTH CARE ACCESS; HUMAN; MARKETING; MEDICAL SPECIALIST; PAIN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PROCESS MODEL; PUBLIC HEALTH;

EID: 0036909491     PISSN: 10601333     EISSN: None     Source Type: Journal    
DOI: 10.1081/CRP-120016436     Document Type: Article

References (41)

1. Fuchs, V. Essays in the Economics of Health and Medical Care; Columbia University Press: New York, 1972.
2. Singer, I. Drugmakers exit the comfort zone. In The State of Health Care in America, 2001; Montvale, NJ, Business & Health, 2001.
3. Freudenheim, M. Drug spending rises rapidly at pharmacies and by mail. New York Times 2002, May 16.
4. Rosenbaum, D.E. States make cuts and increase fees as revenues drop. New York Times 2002, May 16.
5. Rogers, E.M. Diffusion of Innovations; 3rd Edn.; The Free Press: London, 1983.
6. Bass, F.M. A new product growth model for consumer durables. Management Science 1969, 15 (5), 215-27.
7. Williams, J.R.; Hensel, P.J. Changes in physicians' sources of pharmaceutical information: A review and analysis. J. Health Care Mark. 1991,11 (3), 46-60.
8. Avorn, J.; Chen, M.; Hartley, R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am. J. Med. 1982, 73 (1), 4-8.
9. Martinez, B. Medco finds ties bind. Wall Street Journal 2002, May 15.
10. Bennett, J. HMOs are driven to tiers. Wall Street Journal 2002, June 6.
11. Rosenthal, M.; Berndt, E.; Donohue, J. et al.: Promotion of prescription drugs to consumers. New Engl. J. Med. 2002, 346, 498-505.
12. Hensley, S. How generics can cut your drug bills. Wall Street Journal 2002, June 6.
13. NCPA:.
14. Visawanathan, H.; Salmon, J.W. Accrediting organizations and quality improvement. American Journal of Managed Care 2000, 6, 1117-30.
15. Salmon, J. The professional and Corporate Context. In Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs; Davis, P., Ed.; Oxford University Press: New York & London, 1996.
16. Langley, P. The role of pharmacoeconomics guidelines for formulary approval: The Australian experience. Clinical Therapeutics 1993, 15, 1154-76.
17. Detsky, A.S. Guidelines for economic analysis of pharmaceutical products: A draft document for Ontario and Canada. Pharmacoeconomics 1993, 3 (5), 354-61.
18. Glennie, J.L.; Torrance, G.W.; Baladi, J.F. et al.: The revised Canadian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1999, 15 (5), 459-68.
19. Sullivan, S.; Lyles, A.; Luce, B. et al.: AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. Health Plans and Pharmacy Benefits Management Organizations. J. Manag. Care Pharm. 2001, 7 (4), 272-82.
20. Data, J.L.; Willke, R.J.; Barnes, J.R. et al.: Re-engineering drug development: Integrating pharmacoeconomic research into the drug development process. Psychopharmacol. Bull. 1995, 31 (1), 67-73.
21. Johnson, J.; Bootman, J. Pharmacoeconomic analysis in formulary decisions: An international perspective. Am. J. Hosp. Pharm. 1994, 51, 2593-8.
22. Princeton Survey Research Associates: Vital Decisions: How Internet Users Decide what Information to Trust when they or their Loved Ones are Sick, Pew Internet & American Life Project, 2002. http://www.pewinternet.org/reports/pdfs/PIP Vital Decisions May 20; Accessed June 10, 2002.
23. Borzo, G. Consumer drug ads booming: FDA reviews restrictions. American Medical News 1997,1, 37. Feb 10.
24. Lambert, B.L.; Salmon, J.W.; Stubbings, J. et al.: Factors associated with antibiotic prescribing in a managed care setting: An Exploratory Investigation. Soc. Sci. Med. 1997, 45 (12), 1767-79.
25. Lin, S.; Crawford, S.; Salmon, J. Internal and external influences on the adoption of the fentanyl patch. J. Pharm. Mark Manage 2002, (In press).
26. Sultan, F.; Farley, J.U.; Lehmann, D.R.; A meta-analysis of applications of diffusion models. Journal of Marketing Research 1990, 27, 70-7.
27. Salmon, J. An Interview with Drug Firm Representative, 2001. (Personal communication)
28. Coleman, J.S.; Katz, E.; Menzel, H. Medical Innovation: A Diffusion Study; Bobbs-Merrill Company: New York, NY, 1966.
29. Kongstvedt, P. Essentials of Managed Health Care; Aspen Publishers: Frederick, MD, 1999.
30. Norton, J.A.; Bass, F.M. A diffusion theory model of adoption and substitution for successive generations of high technology products. Management Science 1987, 33, 1069-86.
31. Salmon, J. The Corporate Transformation of Health Care, Part II: Perspectives and Implication; Baywood Publishing Company: Amityville, NY, 1994.
32. Relman, A.S. Assessment and accountability: The third revolution in medical care. N. Engl. J. Med. 1988, 319 (18), 1220-2.
33. Institute of Medicine: Crossing the Quality Chasm: A New Health System for the 21st Century. National Academy Press: Washington, DC, Committee on Quality Health Care in America, Institute of Medicine, 2001.
34. Kohn, L.T.; Corrigan, J.M.; Donaldson, M.S. To Err is Human: Building a Safer Health System. Committee on Quality of Health Care in America, Institute of Medicine. National Academy Press: Washington, DC, 2000.
35. Eddy, D. Evidence-based medicine: A practical interpretation. In Academy of Managed Care Pharmacy 14th Annual Meeting, Salt Lake City, UT, 2002.
36. Siu, A.L.; Sonnenberg, F.A.; Manning, W.G. et al.: Inappropriate use of hospitals in a randomized trial of health insurance plans. N. Engl. J. Med. 1986, 315 (20), 1259-66.
37. Wennberg, J.; Gittelsohn, A. Variations in medical care among small areas. Sci. Am. 1982, 246 (4), 120-34.
38. Cleeland, C.S.; Janjan, N.A.; Scott, C.B. et al.: Cancer pain management by radiotherapists: A survey of radiation Therapy Oncology Group Physicians. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47 (1), 203-8.
39. Thompson, A.R.; Savidge, M.A.; Fulper-Smith, M. et al.: Testing a multimedia module in cancer pain management. J. Cancer. Educ. 1999, 14 (3), 161-3.
40. Von Roenn, J.H.; Cleeland, C.S.; Gonin, R. et al.: Physician attitudes and practice in cancer pain management. A Survey from the Eastern Cooperative Oncology Group. Ann. Intern. Med. 1993, 119 (2), 121-6.
41. Clark, H.W. Policy and medical-legal issues in the prescribing of controlled substances. J. Psychoactive Drugs 1991, 23 (4), 321-8.